CLINICAL_TRIALS
trial_result
· 2017-07-18
Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma [Phase 2]
Summary
A Phase 2 clinical trial of Ibrutinib (PCI-32765) in patients with refractory follicular lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma | Phase 2 | Status: COMPLETED